Future Medicine Co Ltd
341170
Company Profile
Business description
Future Medicine Co Ltd is a drug development company. It engages in the development of new drug candidates for anti-inflammatory/anti-fibrosis of non-alcoholic hepatitis (NASH) drugs, oral glaucoma treatments, and chronic kidney disease treatments, as well as targeted and Immuno cancer drugs.
Contact
54 changup-ro
616, 2 Techno Valley Enterprise Growth Center
Gyeonggi-do, Siheung-dong, LH Pangyo-je
Seongnam-si13449
KORT: +82 234293473
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |